Get startedLog in
    Picture of Cereno Scientific AB logo

    CRNO B — Cereno Scientific AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Sweden's Cereno Scientific reports bigger annual loss

    Picture of Cereno Scientific AB logoCereno Scientific AB
    27/02/2026 06:54
    Overview

Swedish biotech firm reported no revenue for 2025, with increased losses compared to 2024

Company secured financing package of up to SEK 665 mln, extending runway to Q4 2027

FDA cleared Phase IIb trial for lead drug CS1 in PAH, starting Q2 2026

Outlook

Cereno Scientific plans to start Phase IIb trial for CS1 in Q2 2026

Company aims to begin Phase II study for CS014 in PH-ILD early 2027

Cereno Scientific's financial runway extends to Q4 2027

Result Drivers

FINANCING ACTIVITIES - Co secured financing package of up to SEK 665 mln, extending financial runway to Q4 2027

FDA CLEARANCE - FDA granted clearance to initiate Phase IIb trial of CS1 for PAH, starting Q2 2026

CS014 DEVELOPMENT FOCUS - Co announced Phase II development focus of CS014 will be PH-ILD

Company press release: ID:nWkr19kW8H

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q4 Adjusted EPS-SEK 0.14
    

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Cereno Scientific AB

    See all news